Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7327634 | 0.84 | HPGD (0.46) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL9715221 | 0.83 | HPGD (0.45) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL10076741 | 0.81 | L3MBTL1 (0.45) | ALDH1A1RAB9ALMNASMN1; SMN2MAPT | |
| SCHEMBL12092089 | 0.81 | L3MBTL1 (0.54) | ALDH1A1RAB9ALMNASMN1; SMN2MAPT | |
| SCHEMBL14860981 | 0.80 | MAPK1 (0.48) | ALDH1A1LMNAMAPTL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL9715397 | 0.78 | F10 (0.42) | F10 | |
| SCHEMBL7975430 | 0.78 | ALDH1A1 (0.72) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL4393639 | 0.76 | TSHR (0.45) | ALDH1A1PARP10LMNAMEN1KMT2A | |
| SCHEMBL13248996 | 0.76 | MAPT (0.46) | ALDH1A1RAB9APARP1PARP15PARP10 | |
| SCHEMBL9315250 | 0.76 | MGLL (0.56) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022497-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | Arrowhead Pharmaceuticals, Inc. | 2017-01-26 | — | — | US | disclosed |
| US-9487556-B2 | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo | Arrowhead Pharmaceuticals, Inc. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487556-B2 | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo | Arrowhead Pharmaceuticals, Inc. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150045573-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | Arrowhead Pharmaceuticals, Inc. | 2015-02-12 | — | — | US | disclosed |
| US-20150045573-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | Arrowhead Pharmaceuticals, Inc. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022497-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | PAM, PLAUR, M6PR | ALDH1A1 4683/4885RAB9A 2557/4885PARP1 1231/4885 |
| US-20150045573-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | PAM, PLAUR, M6PR | ALDH1A1 4683/4885RAB9A 2557/4885PARP1 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.